Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 25, 2016 01:10 ET | Source: Targovax ASA

Targovax ASA: Interim Report second quarter and first half year 2016

OSLO, Norway, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces its...
August 15, 2016 02:04 ET | Source: Targovax ASA

Targovax ASA: Invitation to second quarter 2016 results presentation Thursday 25 August

OSLO, Norway, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, will announce its...
July 06, 2016 01:24 ET | Source: Targovax ASA

Targovax presents encouraging preclinical data on ONCOS-102

OSLO, Norway, July 6, 2016 (GLOBE NEWSWIRE) -- Oslo 6 July 2016: The International Journal of Cancer publishes preclinical in vivo data in a mesothelioma xenograph model, demonstrating synergy of...
July 01, 2016 01:21 ET | Source: Targovax ASA

Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma

OSLO, Norway, July 1, 2016 (GLOBE NEWSWIRE) -- Targovax today announced that the first patient has been dosed in a phase Ib/II clinical trial evaluating ONCOS-102 for the treatment of malignant...
June 14, 2016 02:04 ET | Source: Targovax ASA

Targovax granted US Patent for oncolytic virus ONCOS-102

OSLO, Norway, June 14, 2016 (GLOBE NEWSWIRE) -- Targovax announced today that the US Patent and Trademark office has granted US patent no 9,345,787 for Targovax' lead viral product...
June 09, 2016 02:05 ET | Source: Targovax ASA

Targovax receives regulatory approval in Spain to conduct a clinical trial with its oncolytic virus ONCOS-102

OSLO, Norway, June 9, 2016 (GLOBE NEWSWIRE) -- Targovax receives regulatory approval to conduct a study in Spain to assess its ONCOS-102 product in combination with chemotherapy in patients with...
June 07, 2016 02:19 ET | Source: Targovax ASA

Targovax ASA: Patient recruitment for TG01 immuno-oncology trial completed

OSLO, Norway, June 7, 2016 (GLOBE NEWSWIRE) -- Targovax announces today that the open label Phase I/ II clinical trial of TG01 in combination with gemcitabine of patients with resected pancreatic...
June 02, 2016 02:11 ET | Source: Targovax ASA

Targovax receives approval in Australia to conduct a clinical trial with TG02 - an immunotheraphy treatment targeting RAS mutations

OSLO, Norway, June 2, 2016 (GLOBE NEWSWIRE) -- Targovax receives approval to conduct a study with TG02 and pembrolizumab, a checkpoint inhibitor, in patients with locally recurrent RAS mutated rectal...
May 31, 2016 02:04 ET | Source: Targovax ASA

Targovax to present at forthcoming conferences

OSLO, Norway, May 31, 2016 (GLOBE NEWSWIRE) -- Targovax, a clinical stage immuno-oncology company, developing targeted immunotherapy treatments for cancer patients, announces that members of its...
May 12, 2016 01:10 ET | Source: Targovax ASA

Targovax ASA: Interim report first quarter 2016

Promising data for interim survival analysis of a first cohort of the ongoing open label, phase I/II of TG01/GM-CSF and gemcitabine in patients with resected pancreatic cancer Conducted an...